Qbiotics, page-1240

I will throw a number out there.
So assuming the following points are in place...yes big assumption.

1. The STS trials are successful,
2. The report from the stage 1 H&NC trials is positive
3. The human wound healing Phase 1 trials in Australia is a success
4. The Stelfonta sales have increased to originally forecast (something that will never be revealed)

The market cap should be approx. $1.2 - $1.8B market cap.
Share price of $2.50 - $3.70 in 6 months time.
I have nothing to support this number but MC is generally 3 - 5 times of generated revenue.
If STS and H&NC get to FDA approvals in 3-4 years time and is able to capture 10% - 15% of this available market, the MC could grow to 3 - 4 times.